{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:21:13Z","timestamp":1794410473042,"version":"4.9.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The epidemiological pattern and disease burden of type 2 diabetes have been shifting in China over the past decades. This analysis described the epidemiological transition of type 2 diabetes in the past three decades and projected the trend in the future three decades in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Age-, sex-, and year-specific incidence, prevalence, death, and disability-adjusted life years (DALYs) for people with 15\u00a0years or older and diabetes or high fasting glucose in China and related countries from 1990 to 2021 were obtained from the Global Burden of Disease. We obtained the trends of age-, sex-, and year-specific rates and absolute numbers of incidence, prevalence, deaths, and DALYs attributable to type 2 diabetes in China from 1990 to 2021. Using the Lee\u2013Carter model, we projected the incidence, prevalence, death, and DALYs attributable to type 2 diabetes to 2050 stratified by age and sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The age-standardized incidence of type 2 diabetes was 341.5 per 100,000 persons (1.6 times in 1990) and the age-standardized prevalence was 9.96% (9960.0 per 100,000 persons, 2.5 times in 1990) in China 2021. In 2021, there were 0.9 million deaths and 26.8 million DALYs due to type 2 diabetes or hyperglycemia, as 2.9 and 2.7 times the data in 1990, respectively. The age-standardized rates of type 2 diabetes and hyperglycemia were projected to raise to 449.5 per 100,000 persons for incidence, 18.17% for prevalence, 244.6 per 100,000 persons for death, and 4720.2 per 100,000 persons for DALYs by 2050. The incidence of type 2 diabetes kept growing among individuals under the age of 20 years in the past three decades (128.7 per 100,000 persons in 1990 and 439.9 per 100,000 persons in 2021) and estimating 1870.8 per 100,000 in 2050.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The incidence, prevalence, and disease burden of type 2 diabetes grew rapidly in China in the past three decades. The prevention of type 2 diabetes in young people and the care for elder adults will be the greatest challenge for the country.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003536","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T01:00:08Z","timestamp":1747357208000},"page":"1447-1455","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":43,"title":["Incidence, prevalence, and burden of type 2 diabetes in China: Trend and projection from 1990 to 2050"],"prefix":"10.1097","volume":"138","author":[{"given":"Haojie","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Jia","sequence":"additional","affiliation":[{"name":"Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peige","family":"Song","sequence":"additional","affiliation":[{"name":"School of Public Health and Women\u2019s Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongze","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism and the Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, First Hospital of China Medical University, Shenyang, Liaoning 110001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Jiang","sequence":"additional","affiliation":[{"name":"Teaching & Research Section of General Practice, The General Practice Medical Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"},{"name":"Department of Health Policy and Management, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Fu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"R1-20250620","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(14)70102-0","article-title":"Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment","volume":"2","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R2-20250620","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40273-015-0268-9","article-title":"The economic costs of type 2 diabetes: A global systematic review","volume":"33","author":"Seuring","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"R3-20250620","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"key":"R4-20250620","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1097\/CM9.0000000000002073","article-title":"Visit-to-visit glycated hemoglobin A1c variability in adults with type 2 diabetes: A systematic review and meta-analysis","volume":"135","author":"Qu","year":"2022","journal-title":"Chin Med J"},{"key":"R5-20250620","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/ijms25031882","article-title":"The role of obesity in type 2 diabetes mellitus \u2013 An overview","volume":"25","author":"Chandrasekaran","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R6-20250620","doi-asserted-by":"crossref","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus: Connections in epidemiology, pathogenesis, and treatments","volume":"14","author":"Ruze","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R7-20250620","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1001\/jama.2017.7596","article-title":"Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013","volume":"317","author":"Wang","year":"2017","journal-title":"JAMA"},{"key":"R8-20250620","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S2213-8587(23)00282-6","article-title":"Explaining the high rate of progression from prediabetes to type 2 diabetes in China","volume":"11","author":"Chu","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R9-20250620","doi-asserted-by":"crossref","first-page":"m997","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: National cross sectional study","volume":"369","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"R10-20250620","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1001\/jama.2021.22208","article-title":"Prevalence and treatment of diabetes in China, 2013\u20132018","volume":"326","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"R11-20250620","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/jama.2016.19720","article-title":"Association between diabetes and cause-specific mortality in rural and urban areas of China","volume":"317","author":"Bragg","year":"2017","journal-title":"JAMA"},{"key":"R12-20250620","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1097\/CM9.0000000000003270","article-title":"Burden of non-communicable diseases in China and its provinces, 1990-2021: Results from the Global Burden of Disease Study 2021","volume":"137","author":"Liu","year":"2024","journal-title":"Chin Med J"},{"key":"R13-20250620","doi-asserted-by":"crossref","first-page":"e002529","DOI":"10.1136\/bmjdrc-2021-002529","article-title":"Secular incidence trends and effect of population aging on mortality due to type 1 and type 2 diabetes mellitus in China from 1990 to 2019: Findings from the Global Burden of Disease Study 2019","volume":"9","author":"Li","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"R14-20250620","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R16-20250620","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1161\/STROKEAHA.120.029606","article-title":"Burden of stroke in Europe: Thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years","volume":"51","author":"Wafa","year":"2020","journal-title":"Stroke"},{"key":"R17-20250620","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/CM9.0000000000002189","article-title":"Obesity pandemic in China: Epidemiology, burden, challenges, and opportunities","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J"},{"key":"R18-20250620","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12939-020-01291-4","article-title":"Projected impact of diabetes on the Costa Rican healthcare system","volume":"19","author":"Santamar\u00eda-Ulloa","year":"2020","journal-title":"Int J Equity Health"},{"key":"R19-20250620","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/bmj.322.7299.1389","article-title":"Excess mortality in a population with diabetes and the impact of material deprivation: Longitudinal, population based study","volume":"322","author":"Roper","year":"2001","journal-title":"BMJ"},{"key":"R20-20250620","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archinte.167.9.921","article-title":"Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients","volume":"167","author":"Bethel","year":"2007","journal-title":"Arch Intern Med"},{"key":"R21-20250620","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","article-title":"Epidemiology and determinants of obesity in China","volume":"9","author":"Pan","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R22-20250620","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12939-015-0245-0","article-title":"The influence of socioeconomic status on future risk for developing type 2 diabetes in the Canadian population between 2011 and 2022: Differential associations by sex","volume":"14","author":"Rivera","year":"2015","journal-title":"Int J Equity Health"},{"key":"R23-20250620","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/ije\/dyr029","article-title":"Type 2 diabetes incidence and socio-economic position: A systematic review and meta-analysis","volume":"40","author":"Agardh","year":"2011","journal-title":"Int J Epidemiol"},{"key":"R24-20250620","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/er.2015-1137","article-title":"Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus","volume":"37","author":"Kautzky-Willer","year":"2016","journal-title":"Endocr Rev"},{"key":"R25-20250620","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/obr.12088","article-title":"Leptin levels and risk of type 2 diabetes: Gender-specific meta-analysis","volume":"15","author":"Chen","year":"2014","journal-title":"Obes Rev"},{"key":"R26-20250620","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.2009.976","article-title":"Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis","volume":"302","author":"Li","year":"2009","journal-title":"JAMA"},{"key":"R27-20250620","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/eurheartj\/ehv598","article-title":"Gender in cardiovascular diseases: Impact on clinical manifestations, management, and outcomes","volume":"37","author":"Regitz-Zagrosek","year":"2016","journal-title":"Eur Heart J"},{"key":"R28-20250620","doi-asserted-by":"crossref","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:43Z","timestamp":1750377643000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003536","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"2024-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}